Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

NCT03158805 | Completed Phase 2 Results FDA Drug

• 1 other identifier: 2017-1579
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will reduce body weight and improve metabolic variables in obese or overweight patients with BP without worsening psychiatric symptoms. The investigators predict that liraglutide 3.0 mg sc injection will display greater efficacy as compared to placebo in decreasing body weight in patients with BP who are obese or overweight. To prove this hypothesis, investigators will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP. The investigators have chosen BP rather than another SMI because it is the most common SMI (more common than schizophrenia or schizoaffective disorder) and has a particularly strong association with obesity.

Conditions

Bipolar Disorder; Obesity

Outcome Measures

Primary Outcomes (1)

• Percent Change in Body Weight

  Percent change in body weight over 40 weeks

  40 week

Study Arms (2)

Active drug

ACTIVE COMPARATOR

LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

Drug: LIRAGLUTIDE

Placebo

PLACEBO COMPARATOR

Placebo (no active drug)

Other: Placebo

Interventions

LIRAGLUTIDE DRUG

3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

Also known as: Saxenda

Active drug

Placebo OTHER

Placebo injection

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and women, ages of 18-65 years, inclusive.
• Participants will have a DSM-5 bipolar disorder that is clinically stable.
• Participants will have received a stable major psychotropic drug regimen (except for minor dosage adjustments) for at least 3 months prior study entry. Major psychotropic drugs are antipsychotics, mood stabilizers, and antidepressants. Subjects may have had changes in adjunctive benzodiazepines and hypnotic agents.
• Participants will be obese (defined as a BMI ≥ 30 mg/kg2) or overweight (defined as BMI ≥ 27 kg/m2) with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia.
• Participants in treatment for a weight-related comorbidity (hypertension, type 2 diabetes, and/or dyslipidemia) must be on a stable and allowed treatment regimen for that condition for at least 3 months prior to study enrollment.
• Participants will be able to provide informed consent before any trial-related activities.

You may not qualify if:

• Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures. The following are considered to be adequate methods of birth control: 1.Intrauterine device (IUD); 2. Barrier protection; 3.Contraceptive implantation system (Norplant); 4.Oral contraceptive pills; 5. A surgically sterile partner; and 6. Abstinence. Women who are \> 2 years post-menopausal or surgically-sterile are not considered of childbearing potential. All female participants will have a negative pregnancy test prior to randomization.
• Participants who have made a suicide attempt in the last 10 years, who are displaying clinically significant psychotic features, suicidality, or homicidality on mental status examination, or who have suicidal ideation or behavior as assessed with the C-SSRS.
• Participants who are receiving behavioral weight loss treatment (BWLT) (e.g., Weight Watchers) that was begun within the 3 months before study entry. Participants who are receiving BWLT that was started 3 months prior to the beginning of the study will be allowed to continue to receive their BWLT during the trial only if they have had no weight loss in the past 3 months and they agree to not make any changes in the frequency or nature of their BWLT during the course of the drug trial.
• A DSM-5 diagnosis of a substance-related or addictive disorder (except a tobacco-related disorder) within the 3 months prior to enrollment.
• A DSM-5 diagnosis of dementia, a psychotic disorder, or a depressive disorder.
• History of any psychiatric disorder which might interfere with a diagnostic assessment, treatment, or compliance.
• Have a history of a structural cardiac abnormality, valvular cardiac disease, cardiomyopathy, serious heart rhythm abnormality, coronary artery disease, congestive heart failure, stroke, or other serious cardiovascular problem.
• Have an ECG with significant arrhythmias or conduction abnormalities, which in the opinion of the physician investigator preclude study participation.
• Have clinically relevant abnormal laboratory results.
• Participants requiring treatment with any drug which might interact adversely with or obscure the action of the study medication. This includes anti-obesity drugs, psychostimulants, modafinil or armodafinil, topiramate or zonisamide, and antipsychotics. Participants receiving metformin at a stable dose for ≥ 3 months can be included.
• Participants receiving GLP-1 based therapies, sodium-glucose co-transporter 2 inhibitors (SGLT2s), thiazolidinediones, sulfonylureas, or insulin.
• Participants with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• Participants who have received any investigational medication within three months prior to randomization.
• Participants previously screen-failed or randomised to participate in this trial.
• Participants who have a known or suspected allergy to liraglutide 3.0 mg sc injection, its constituents, or related products.

Sponsors & Collaborators

• Lindner Center of HOPE: lead

Study Sites (1)

Lindner Center of HOPE

Mason, Ohio, 45040, United States

Location

Related Publications (1)

• McElroy SL, Guerdjikova AI, Blom TJ, Mori N, Romo-Nava F. Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder. J Clin Psychopharmacol. 2024 Mar-Apr 01;44(2):89-95. doi: 10.1097/JCP.0000000000001803. Epub 2024 Jan 15.

  PMID: 38227621 DERIVED

MeSH Terms

Conditions

Bipolar Disorder; Obesity

Interventions

Liraglutide

Condition Hierarchy (Ancestors)

Bipolar and Related Disorders; Mood Disorders; Mental Disorders; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Glucagon-Like Peptide 1; Glucagon-Like Peptides; Proglucagon; Gastrointestinal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Limitations and Caveats

The small sample size may have compromised the study's ability to detect important effects. Premature termination rate was high and treatment duration was relatively short. Only individuals with stable BD were enrolled, and therefore results cannot be generalized to individuals with unstable BD.

Results Point of Contact

• Title: Susan McElroy
• Organization: Lindner Center of HOPE

susan.mcelroy@lindnercenter.org

5135360700

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Research Officer

Model Details: We will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP.

Study Record Dates

• First Submitted: May 15, 2017
• First Posted: May 18, 2017
• Study Start: April 26, 2017
• Primary Completion: October 11, 2022
• Study Completion: January 1, 2023
• Last Updated: March 12, 2025
• Results First Posted: March 27, 2024

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)